Please login to the form below

Not currently logged in
Email:
Password:

HEC

This page shows the latest HEC news and features for those working in and with pharma, biotech and healthcare.

Merck plans expanded filing for Emend this year

Merck plans expanded filing for Emend this year

The single-dose regimen is already approved for use in highly-emetogenic chemotherapy (HEC), but Merck says it will now file the results with regulators later this year to broaden

Latest news

  • Roche eases developing world Tamiflu access

    Sub licences for manufacture have been issued to Hetero in India, Shanghai Pharma and HEC in China, and a technology transfer issued to Aspen Pharmaceuticals in South Africa.

  • GSK files NDA in the US

    Patients who have undergone highly emetogenic chemotherapy (HEC) have a 90 per cent chance of experiencing CINV, which can last for up to five days. ... Phase III trial of the new drug, involving HEC patients, showed a patient response rate of 86 per

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics